In this context, MYC amplification and activation of the MYC pathway are hallmark features of the basal subtype, with MYC amplification observed in 55.6% of cases and associated with aggressive disease and poor prognosis.3 In ovarian and endometrial cancers, TCGA analyses showed that MYC was amplified in 30.7% and 10.8% of tumors, respectively.3 In other genomic analyses in NSCLC,20 renal clear cell carcinoma21 and PDAC22 patients, MYC amplification was observed in 31%, 23% and 14%, respectively. This evidence concerns the gene MYC and endometrial cancer.